Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-of-1 antiarrhythmic therapy optimization in Andersen-Tawil syndrome and MEPPC
NL-OMON60790Phase 4Not yet recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of flecainide, propranolol, carvedilol and quinidine in Andersen-Tawil syndrome (ATS) and Multifocal Ectopic Purkinje-related Premature Contractions (MEPPC) (3 arms), sponsored by Amsterdam University Medical Center. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
flecainidepropranololcarvedilolquinidine
03
Conditions
Andersen-Tawil syndrome (ATS)Multifocal Ectopic Purkinje-related Premature Contractions (MEPPC)
Beyond the preview
Go deeper on NL-OMON60790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60790.